If I'm reading that correctly, and I am not certain that I am.
100% vs 17%..... is actually saying of the Remestemcel Lots, that when injected reduced IL2Ra:
The remestemcell lots that reduced IL2Ra in the potency assay, by greater than the median ammount ( middle of all the reduction ammounts ) - there was 100 % survival.
The remestemcel lots that reduced IL2Ra by less than the median ammount ( below the middle of all injections ) - there was only 17% survival.
That would possibly indicate - if they increased their IL2ra potency assay levels to be the median ammount above as a minimum, then so far 100% survival in high MAP scores.
On the potency side IL2Ra in vitro ( potency assay ) reduction is linked to survival for severe inflammed disease states, and if the potency assay screens for IL2ra lowering ability, then the potency assay through the MOA is linked to survival.
JB?
MESOBLAST CURES SR-aGVHD IN CHILDREN, page-2
-
- There are more pages in this discussion • 80 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.01 | 98.0¢ | $4.720M | 4.751M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 171759 | 98.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 16000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |